Marty Makary

President Donald Trump has selected Dr. Heidi Overton, a White House domestic policy aide and physician, to lead the U.S. Food and Drug Administration (FDA). If confirmed by the Senate, Overton would replace Marty Makary, who resigned after clashes with the administration. The nomination faces strong bipartisan criticism, particularly from Republican senators over her role in vaccine policy and conservative health stances. The FDA has lost over 3,000 staff and faces trust and politicization challenges.

11 reports · 5 sources · Updated Aug 21, 01:00 PM UTC

The U.S. FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, for adults aged 50 and older. Clinical trials showed 26.6% greater efficacy than traditional shots. The approval followed a contentious review process, including an initial refusal and subsequent reversal. The vaccine is expected for the 2026-2027 flu season. The decision occurs amid HHS Secretary Robert F. Kennedy Jr.'s efforts to cut federal funding for mRNA vaccine research, including canceling $500 million in contracts.

6 reports · 3 sources · Updated Aug 10, 11:13 PM UTC

Marty Makary resigned as FDA Commissioner in May 2026 amid controversy over his opposition to the Trump administration's push to approve fruit-flavored e-cigarettes, which he argued would attract minors. Despite the controversies, the article argues Makary enacted the most significant FDA modernization in decades. Key reforms include reducing drug review times from a year to 1-2 months, increasing generic drug approvals by 20%, deploying artificial intelligence to speed up reviews, issuing new guidance for psychedelics, creating a 'plausible mechanism' pathway for rare disease drugs, and changing estrogen labels. The analysis, written by a colleague who served with Makary on a think tank advisory board, asserts that while individual reforms may be debated, collectively they represent major improvements to the FDA's regulatory approach.

1 reports · 1 sources · Updated Jul 22, 08:15 PM UTC

The U.S. Food and Drug Administration faces significant instability as Dr. Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research, departs just days after Commissioner Marty Makary’s resignation. This leadership crisis, occurring under the second Trump administration, stems from internal conflicts over flavored e-cigarette access and controversial vaccine safety reviews. With multiple high-level exits and temporary appointments, the agency grapples with intense political pressure from administration allies, raising concerns about regulatory integrity and public trust in federal health oversight.

5 reports · 5 sources · Updated May 17, 05:52 PM UTC

The Trump administration’s decision to expand the availability of flavored e-cigarettes has triggered significant internal dissent within the Make America Healthy Again (MAHA) movement and among federal health officials. The regulatory shift, which creates a pathway for tobacco companies to sell flavored vapes and includes the first FDA authorization for fruit-flavored devices, led to the resignation of Health Secretary Robert F. Kennedy’s senior spokesperson, Richard Danker. In his resignation letter, Danker warned that these products would appeal to children, increasing risks of nicotine addiction, lung damage, and cancer. The policy also contributed to the removal of FDA Commissioner Marty Makary, who opposed the changes. Additionally, prominent MAHA influencers, such as Alex Clark of Turning Point USA, expressed frustration, arguing that the move validates concerns that special interest groups, particularly the tobacco industry, are exerting undue influence over White House decisions. This development highlights a growing rift between the administration’s deregulatory actions and the public health priorities advocated by key allies in the MAHA coalition.

1 reports · 1 sources

This weekly roundup from The Dispatch covers four major developments. First, Marty Makary’s turbulent 13-month tenure as FDA commissioner ends amid controversy and a policy break with President Trump on vaping regulations. Second, the U.S. and Ukraine are negotiating a strategic partnership to develop attack drones, allowing Ukraine to monetize its expertise to fund its war against Russia, though critics note this overlooks defensive capability gaps. Third, the article challenges the growing bipartisan skepticism toward GDP growth, arguing that both leftist 'degrowth' advocates and populist right-wing critics dismiss economic output metrics to the detriment of sound policy. Finally, President Donald Trump arrives in Beijing for a high-stakes three-day summit with Chinese leader Xi Jinping, marking the first in-person meeting between the two leaders since 2017. This diplomatic engagement occurs against a backdrop of heightened tensions, including ongoing trade disputes and conflicts in the Middle East, signaling a potential shift in U.S.-China relations after years of adversarial rhetoric.

1 reports · 1 sources

In an interview with Pharmaceutical Executive, Dr. Jeremy Levin, author of 'Biotech in the Balance,' discusses the structural challenges facing the biotechnology industry. Amidst turbulent changes in US health agency leadership, including reports that Marty Makary is out as FDA head, Levin argues that the biotech sector is fundamentally mismatched with current capital market structures. He explains that unlike digital products, which can be launched and tweaked quickly, biotech requires a decade-long development timeline. This long timescale is incompatible with stock markets designed for rapid returns, leading to severe penalties for companies when scientific adjustments are needed. Levin emphasizes that biotech should be recognized as a national strategic asset, noting that the industry produces 70% of the medicines sold by large pharmaceutical companies. He calls for policy changes to address misinformation, reduce the politicization of medical research, and create a financial environment that supports the unique long-term risks inherent in drug development.

1 reports · 1 sources

Following the resignation of FDA Commissioner Marty Makary, nearly 400 leaders from the biopharma industry have signed a letter endorsing Dr. Richard Pazdur as the next commissioner. Addressed to US President Donald Trump, the coalition of biotech CEOs, investors, and patient advocates argues that Pazdur’s 26-year tenure at the agency provides the necessary stability amid a current crisis of confidence. The letter cites decisional volatility, staff exodus, and eroding scientific predictability under recent leadership as critical issues requiring an experienced hand. Pazdur, who previously headed the Center for Drug Evaluation and Research (CDER) and founded the Oncology Center of Excellence, is credited with streamlining cancer drug approvals through initiatives like Project Orbis. Although he retired in December 2025 due to disagreements with the administration's direction, industry leaders believe his track record offers the unimpeachable scientific credibility needed to restore trust. The endorsement emphasizes not just support for Pazdur, but a broader demand for FDA leadership that maintains regulatory rigor and speed despite political pressures. Kyle Diamantas currently serves as acting commissioner while the search for a permanent successor continues.

1 reports · 1 sources

The U.S. Food and Drug Administration (FDA) has withheld approval for Replimune’s genetically engineered melanoma treatment, RP1, despite clinical trials showing tumor shrinkage in one-third of participants. The decision has sparked intense debate within the medical community, with oncologists describing it as devastating for patients facing life-threatening conditions. Critics argue that FDA Commissioner Marty Makary, who recently resigned, altered the agency’s culture by ignoring professional advice and acting under political pressure from the Trump administration and HHS Secretary Robert F. Kennedy Jr. While industry analysts acknowledge legitimate concerns regarding the trial design, they contend that Makary’s erratic leadership and accusations of corporate corruption against Replimune have created dangerous uncertainty. This move is seen as part of a broader pattern where senior officials suppressed or accelerated drug approvals based on political behest rather than scientific merit. The rejection raises fears about the future of drug development and regulatory trust, leaving stakeholders unsure whether decisions are grounded in science or political maneuvering. With melanoma causing approximately 8,500 deaths annually in the U.S., the blockage potentially impacts thousands of patients who might have benefited from the innovative therapy.

1 reports · 1 sources

The US Supreme Court has issued an order preserving women's access to mifepristone, the drug used in the most common method of abortion, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail delivery of the medication. This emergency relief allows patients to obtain the drug through pharmacies or via mail without immediate disruption, likely maintaining the status quo until at least next year as the case proceeds through appeals. The ruling grants requests from manufacturers Danco Laboratories and GenBioPro, overturning a Fifth Circuit Court of Appeals decision that favored Louisiana’s lawsuit against FDA regulations. Justices Clarence Thomas and Samuel Alito dissented, arguing the manufacturers are not entitled to protect profits from what they termed illegal activities under the Comstock Act. The case highlights ongoing tensions between anti-abortion groups and the FDA regarding telehealth prescriptions and safety reviews. With medication abortions accounting for nearly two-thirds of all procedures in 2023, this decision significantly impacts reproductive healthcare access across the United States, particularly in states with strict abortion bans.

1 reports · 1 sources

The U.S. Supreme Court has issued an emergency stay allowing continued access to medication abortion via telemedicine and mail, effectively blocking a recent ruling by the 5th U.S. Circuit Court of Appeals. The appellate court had previously mandated in-person dispensing of mifepristone, citing conflicts with Louisiana’s abortion ban. This Supreme Court decision maintains the status quo pending further appeals, preserving a Biden-era pandemic policy that significantly expanded access to reproductive healthcare. Justices Clarence Thomas and Samuel Alito Jr. dissented from the order. The case involves pharmaceutical manufacturers Danco Laboratories LLC and GenBioPro Inc., who argued that restricting mail distribution would create regulatory chaos contradicting FDA policies. Mifepristone has been available in the U.S. for 25 years, with medication abortions accounting for 63 percent of all procedures in 2023. The ruling occurs amidst political tension, following the resignation of FDA Commissioner Marty Makary and a renewed Senate Democratic resolution affirming the drug's safety. This development is critical for patients in Republican-led states where access to abortion services is increasingly restricted.

1 reports · 1 sources

Marty Makary has resigned as Commissioner of the Food and Drug Administration (FDA) following intense pressure from the Trump administration to authorize fruit-flavored e-cigarettes. The decision highlights growing chaos within the Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., whose anti-vaccine stances and management style have drawn significant criticism. Makary reportedly resisted approving kid-friendly vape flavors, such as menthol and mango, due to public health concerns regarding youth addiction. However, President Trump allegedly scolded Makary for delaying the approvals, which align with his campaign promises and tobacco industry interests. Following the authorization of these products, Makary stepped down. The article emphasizes that HHS is currently suffering from a severe leadership vacuum, with key positions like the CDC Director and Surgeon General filled by acting officials rather than Senate-confirmed appointees. This lack of permanent leadership, combined with controversial policy shifts on vaccines and vaping, suggests the agency is operating without clear direction, potentially jeopardizing American public health amidst ongoing challenges like a significant measles outbreak.

1 reports · 1 sources

The U.S. Supreme Court has issued an order preserving women's access to mifepristone, the primary drug used in medication abortions, while a legal challenge proceeds. The decision rejects lower-court restrictions that would have mandated in-person doctor visits and halted mail-order distribution of the drug. This emergency relief allows patients to continue obtaining mifepristone through pharmacies and telehealth services without interruption, likely until at least next year. The ruling grants requests from manufacturers Danco Laboratories and GenBioPro, who are appealing a federal appeals court decision favoring Louisiana’s attempt to roll back FDA regulations. Justices Clarence Thomas and Samuel Alito dissented, arguing the manufacturers profit from illegal activities under state laws and the Comstock Act. The case highlights ongoing tensions between anti-abortion groups and the FDA regarding drug safety and access protocols. While abortion-rights advocates expressed relief, they emphasized that healthcare access should not depend on judicial outcomes. Conversely, anti-abortion groups view the decision as disappointing but maintain hope for a full hearing. This development occurs four years after the overturning of Roe v. Wade, continuing the national debate over reproductive rights.

1 reports · 1 sources

The U.S. Supreme Court has issued an order preserving access to mifepristone, a key medication used in abortions, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail-order distribution of the drug. This ruling ensures that women can continue obtaining mifepristone through pharmacies and telehealth services without interruption, at least until the case proceeds further, potentially into next year. The emergency stay was granted in favor of the drug's manufacturers, Danco Laboratories and GenBioPro, who appealed a federal appeals court decision. Justices Clarence Thomas and Samuel Alito dissented, arguing against the manufacturers' actions. The lawsuit, initiated by Louisiana, challenges FDA regulations approved in 2000 and modified five years ago to allow remote prescribing. Anti-abortion groups are pressuring the Trump administration to expedite reviews aimed at restricting access, citing safety concerns despite FDA affirmations of the drug's efficacy. This development occurs four years after the overturning of Roe v. Wade, highlighting ongoing national debates over reproductive rights and federal regulatory authority.

1 reports · 1 sources

The US Supreme Court has issued an order preserving nationwide access to mifepristone, a widely used abortion medication, while legal challenges proceed. The decision rejects lower-court restrictions that would have halted mail delivery and required in-person doctor visits, effectively maintaining the status quo established by the FDA five years ago. This emergency stay grants relief to manufacturers Danco Laboratories and GenBioPro, ensuring uninterrupted access via pharmacies and mail at least until next year. Justices Clarence Thomas and Samuel Alito dissented, arguing that the companies profit from what they termed a criminal enterprise violating the Comstock Act and state laws. The case originates from a lawsuit by Louisiana, which contends that federal prescribing rules undermine its state abortion ban and question drug safety, despite FDA affirmations. The ruling occurs within a charged political environment under President Donald Trump’s administration, where anti-abortion groups are pressuring the FDA for stricter regulations. This development follows the recent resignation of FDA Commissioner Marty Makary amid criticism from Trump allies. The court's action highlights the continuing legal and political friction surrounding abortion access four years after the overturning of Roe v. Wade.

1 reports · 1 sources

The U.S. Supreme Court has issued an order preserving women's access to mifepristone, the most widely used medication for abortion, while legal challenges continue. The decision rejects lower-court restrictions that would have mandated in-person doctor visits and halted mail-order distribution of the drug. This emergency relief allows uninterrupted access at least until next year as the case proceeds through potential appeals. The lawsuit, initiated by Louisiana, argues that current FDA regulations undermine state abortion bans and question the drug's safety, despite longstanding FDA determinations of its efficacy. Anti-abortion groups are pressuring the Trump administration to accelerate regulatory reviews to restrict telehealth prescriptions, creating political tension for the Republican leadership. Meanwhile, medical groups and pharmaceutical companies warn that limiting access could disrupt the broader drug approval process. The Court's action follows a similar dispute three years ago, where it ultimately dismissed a challenge from anti-abortion physicians on standing grounds. The Biden-era FDA had previously eased restrictions, but the current political climate remains charged as both sides interpret the federal government's silence in this case as significant.

1 reports · 1 sources

Following the resignation of FDA Commissioner Marty Makary, MD, MPH, diverse stakeholders across the healthcare and regulatory sectors are urging a return to standard operational procedures at the Food and Drug Administration. Dr. Makary stepped down in protest against the agency's controversial decision to authorize flavored products, a move that sparked significant internal and external debate. His departure has intensified calls for leadership that prioritizes established regulatory frameworks and scientific rigor over political or commercial pressures. Industry experts, patient advocacy groups, and medical professionals are emphasizing the need for predictability and consistency in FDA decision-making processes to maintain public trust and ensure patient safety. The situation highlights ongoing tensions within the agency regarding its regulatory direction and the balance between innovation and strict oversight. As the search for a new commissioner begins, the primary demand from the community is for a leader who will restore 'regular order' and uphold the integrity of the FDA's mission. This development underscores the critical role of stable leadership in shaping public health policy and regulatory outcomes in the United States.

1 reports · 1 sources

This week's episode of STAT News' podcast, 'The Readout LOUD,' focuses on significant developments in health politics. The discussion centers on two major stories: the departure of Marty Makary as FDA commissioner and the precarious position of Senator Bill Cassidy in his upcoming Republican primary election. FDA reporter Lizzy Lawrence analyzes Makary's exit, exploring the reasons behind his departure, the potential longevity of his policies, and details regarding his acting replacement, Kyle Diamantas. Simultaneously, Washington correspondent Chelsea Cirruzzo examines the closely watched Senate primary in Louisiana, where Cassidy, the chair of the Senate Health Committee, faces challenges from two rivals, including a candidate backed by former President Donald Trump. The outcome of this primary is highlighted as having far-reaching implications for the future of Trump's health care agenda. The episode serves as a comprehensive overview of these intersecting political and regulatory shifts within the US healthcare landscape, offering insights into how personnel changes at the FDA and electoral politics may influence future health policy directions.

1 reports · 1 sources

STAT News Executive Editor Rick Berke introduces "The Deadliest Drug," a new investigative series exposing the United States' systemic failure to address excessive alcohol use. The report highlights that alcohol causes 178,000 deaths annually, characterizing this crisis as a generational failure involving medical systems, public health authorities, industry, and government. The investigation, conducted by reporters Isabella Cueto and Lev Facher, includes interviews with over 100 experts and analysis of scientific literature and lobbying disclosures. Key findings include a seismic shift in 12-step programs, a rise in pregnancy-related drinking, and a unique category of liver disease. The series criticizes the Trump administration for missing opportunities to mitigate the epidemic. Additionally, the letter covers recent developments at the FDA, including the resignation of Commissioner Marty Makary, and political updates regarding Senator Bill Cassidy. The article serves as both an introduction to the investigative series and a promotion for STAT+ subscriptions, offering readers access to deep-dive journalism on health, medicine, and policy issues.

1 reports · 1 sources

Richard Danker, the assistant secretary for public affairs at the Department of Health and Human Services (HHS), has resigned from his position under Health Secretary Robert F. Kennedy Jr. The resignation stems from a disagreement over the Food and Drug Administration's recent authorization of fruit-flavored e-cigarettes. In a letter addressed to President Donald Trump, Danker argued that approving these products undermines the department's guidance on youth risks associated with flavored nicotine. He asserted that the decision exposes children to significant health dangers, including nicotine addiction, lung damage, and increased cancer risk. This incident highlights internal tensions within the Trump administration regarding its 'Make America Healthy Again' agenda. An HHS spokesperson responded by emphasizing the need for political appointees to execute the mission with discipline, suggesting that those who lose sight of their responsibilities are free to leave. The controversy also involves former FDA Commissioner Marty Makary, who reportedly clashed with the White House over similar pressures to authorize flavored vapes. The FDA recently approved four new devices by Glas, including mango and blueberry flavors, marking a notable shift in regulatory stance despite ongoing efforts to remove illicit vapes targeting minors.

1 reports · 1 sources

The Trump administration has initiated the search for the next leader of the Food and Drug Administration (FDA) following the departure of Marty Makary. According to STAT News, the administration possesses a comprehensive wish list of criteria and qualifications for the incoming commissioner, signaling a strategic shift in regulatory leadership. The article, part of STAT's D.C. Diagnosis newsletter, highlights the political dynamics surrounding this high-level appointment. While specific candidates are not detailed in the available text, the focus remains on the transition process and the priorities set by the current White House for the agency's future direction. Additionally, the newsletter briefly touches upon Louisiana politics, noting sympathy for Senator Bill Cassidy in a separate context. This development underscores the intersection of health policy and political strategy, as the FDA plays a critical role in public health regulation. The exclusion of Makary and the subsequent hunt for his replacement mark a significant moment for the agency, with implications for pharmaceutical approvals, medical device regulations, and broader health initiatives under the Trump administration's tenure.

1 reports · 1 sources

Mike Banks, the U.S. Border Patrol Chief, has announced his immediate retirement after 37 years of service, marking a significant departure from the Trump administration. His exit represents at least the fifth high-profile official to leave the Department of Homeland Security this year, highlighting ongoing instability within the agency tasked with implementing the president's mass deportation initiatives. Banks stated that he felt it was time to pass the reins after getting the agency back on course. This resignation follows a series of other notable departures, including the firing of Homeland Security Secretary Kristi Noem and the resignations of ICE Acting Director Todd Lyons and FDA Commissioner Marty Makary. The wave of exits extends beyond homeland security, with Attorney General Pam Bondi and Labor Secretary Lori Chavez-DeRemer also leaving their posts recently. Banks maintained a lower public profile compared to counterparts involved in aggressive immigration enforcement raids. His departure underscores the turbulent personnel changes characterizing the second year of Trump's presidency, as the administration grapples with internal shifts while pursuing stringent border and immigration policies.

1 reports · 1 sources

Dr. Marty Makary resigned as FDA commissioner following a confirmation from White House officials that his departure was communicated via text message. This unusual method of resignation, highlighted by a post from President Donald Trump on Truth Social, has sparked a broader discussion on professional workplace etiquette. While the political shake-up dominates headlines, career experts emphasize that resigning by text is generally inappropriate for high-level positions. Bonnie Dilber from Zapier and HR consultant T. Tara Turk-Haynes advise that senior executives should prioritize in-person conversations followed by formal written letters to maintain professional relationships. They warn that poor exit strategies can negatively impact future employment opportunities and reference checks. Although text resignations are more acceptable in high-turnover retail or frontline roles, white-collar professionals are expected to adhere to stricter protocols, including providing adequate notice periods. The article underscores the importance of leaving on good terms, offering constructive feedback during exit interviews, and avoiding emotional responses that could damage one's long-term reputation in small professional circles.

1 reports · 1 sources

The Trump administration has initiated the search for a new Food and Drug Administration (FDA) commissioner following the resignation of Marty Makary. According to reports, the ideal candidate is expected to rebuild trust with agency staff, prioritize food policy reforms, and continue driving changes in drug approval processes. This leadership transition occurs against a backdrop of broader health news, including cautious optimism regarding three years of declining overdose deaths, though concerns remain. Additionally, the Centers for Disease Control and Prevention (CDC) is actively responding to a hantavirus outbreak, with STAT’s Helen Branswell providing insights into the journalistic challenges of covering such public health crises. The article also highlights the work of Morning Rounds writer Theresa, who focuses on gender-affirming care, reproductive health, and mental health. These developments underscore the dynamic nature of current US health policy and public health management, reflecting ongoing efforts to address critical medical and regulatory issues within the federal healthcare infrastructure.

1 reports · 1 sources

Kyle Diamantas has been appointed as the acting commissioner of the Food and Drug Administration (FDA), succeeding Marty Makary following his resignation. According to analysis by STAT+ senior writer Adam Feuerstein, Diamantas is expected to serve as a stabilizing, drama-free caretaker for the agency. This leadership transition, while typically a source of anxiety for industry stakeholders, is reportedly viewed with confidence by the biotechnology sector and investors. Diamantas previously served as the FDA’s top food regulator, bringing relevant administrative experience to the role. The article suggests that his appointment minimizes uncertainty for drug development companies and Wall Street observers who track the biotech industry closely. As an acting commissioner, Diamantas is anticipated to maintain operational continuity without introducing significant policy disruptions or controversial changes during his tenure. This assessment highlights the market's relief regarding the stability of regulatory oversight during this interim period, ensuring that the critical functions of the FDA continue smoothly amidst the leadership change.

1 reports · 1 sources

In an interview with Pharmaceutical Executive, Dr. Jeremy Levin, author of 'Biotech in the Balance,' discusses the detrimental impact of misinformation on evidence-based medicine and the biotechnology industry. Amidst turbulent leadership changes at US health agencies, including the reported removal of Marty Makary from the FDA, Levin emphasizes the need to address capital market relationships and resist the politicization of medical research. He highlights the media's failure to curate information, noting that outlets often repeat unverified claims rather than verifying them. Levin cites the retracted Lancet article linking MMR vaccines to autism as a prime example of how scientific errors, when not aggressively corrected by publications, lead to long-term public distrust and vaccine hesitancy. This misinformation has contributed to the resurgence of measles in the United States and poses significant risks for future pandemic responses. Levin argues that scientific journals and media must take greater responsibility for clarifying past errors to combat the spread of false narratives that undermine public health initiatives and strategic industry stability.

1 reports · 1 sources

Marty Makary has resigned from his position at the Food and Drug Administration (FDA), a move that may alleviate some immediate political pressure on the Trump administration by removing one of its more controversial health officials. However, this leadership change does not resolve the underlying challenges facing the agency. The incoming FDA chief will inherit a difficult landscape characterized by significant political interference, potential funding cuts, and the complex task of balancing scientific integrity with the political demands of the "Make America Healthy Again" initiative. This situation highlights the ongoing tension between public health governance and political agendas within the current administration. While Makary's departure might offer a brief respite from specific controversies associated with his tenure, the structural and political headwinds remain intact. The next leader must navigate these persistent issues while maintaining the agency's credibility and operational effectiveness. The article suggests that the core problems affecting the FDA are systemic rather than purely personal, implying that future appointees will face similar scrutiny and obstacles regardless of individual leadership styles. This development underscores the volatile nature of health policy under the current political climate.

1 reports · 1 sources

Marty Makary has resigned as the Commissioner of the Food and Drug Administration (FDA), concluding a turbulent tenure marked by significant opposition from various stakeholders. Appointed initially as a critic of the agency, Makary faced intense backlash from both pharmaceutical developers and anti-abortion groups during his time in office. His departure follows reports in the Wall Street Journal that President Donald Trump had approved plans to dismiss him. Although President Trump publicly claimed ignorance regarding the firing plans when questioned by reporters, the resignation occurred just four days after the initial report surfaced. The article highlights the political and industrial pressures that characterized Makary's leadership, noting his involvement in recent executive actions, such as those concerning psychedelics. This event underscores the ongoing tensions between regulatory leadership, the pharmaceutical industry, and political appointees within the current administration. The resignation marks a significant shift in the FDA's direction and reflects the broader challenges faced by health regulators in navigating complex political landscapes.

1 reports · 1 sources

Marty Makary has resigned from his position as the Commissioner of the U.S. Food and Drug Administration (FDA) following a significant policy disagreement with President Donald Trump. The central point of contention involved the authorization and regulation of fruit-flavored electronic cigarettes. This high-profile departure highlights the ongoing tensions between public health regulatory frameworks and political directives regarding vaping products. In the wake of Makary's resignation, Kyle Diamantas has been appointed as the acting commissioner to lead the agency during this transitional period. The incident underscores the complex interplay between scientific oversight and executive decision-making in the realm of public health policy. As the FDA navigates these challenges, the focus remains on balancing consumer safety with industry regulations. The resignation marks a pivotal moment for the agency, potentially influencing future approaches to nicotine product approvals and broader tobacco control strategies within the United States.

1 reports · 1 sources

Marty Makary has resigned from his position as Commissioner of the U.S. Food and Drug Administration (FDA) following a significant policy disagreement with President Donald Trump regarding the approval of flavored e-cigarettes. The departure highlights a sharp clash within the administration over public health regulations and the vaping industry. Makary's resignation creates a leadership vacuum at the agency, with Kyle Diamantas appointed to serve as the acting commissioner until a permanent replacement is confirmed. This event underscores the ongoing tension between regulatory bodies and political leadership concerning tobacco and vaping products, which have been subject to intense scrutiny due to health concerns, particularly among youth. The decision to resign rather than compromise on the approval process suggests deep ideological or procedural divides within the executive branch's approach to consumer health safety. The incident draws attention to the influence of political pressure on scientific and regulatory decisions within federal agencies, raising questions about the autonomy of health officials in the current administrative landscape.

1 reports · 1 sources